

Special Issue

Vaccine Adjuvants Targeting Emerging and Re-emerging Livestock Infectious Disease: Boosting Stronger Immune Responses

Message from the Guest Editors

Emerging and re-emerging infectious diseases caused by viruses, bacteria, fungi and parasites are causing significant morbidity and mortality not only in humans, but also in various livestock, including cattle, pigs, sheep, birds, and others. Among numerous strategies, vaccination is the most effective approach to preventing and controlling infectious diseases. In most cases, vaccines need a suitable adjuvant and delivery carrier to trigger an adequate immune response. However, the availability of veterinary vaccine adjuvants and carriers is limited. Therefore, it is urgent to formulate novel strategies to develop safe and efficient adjuvants and vaccine delivery carriers to control various animal infectious diseases. The aim of this Special Issue is to present research on the development and understanding of novel adjuvants and vaccine delivery carriers for emerging and re-emerging infectious diseases in various livestock. The following research themes are welcome:

- Novel adjuvants for veterinary vaccines
- Novel vaccine delivery carriers
- Understanding the underlying molecular mechanisms of novel vaccine adjuvants and delivery carriers

Guest Editors

Prof. Dr. Wei Xu

Prof. Dr. Kai Zhao

Prof. Dr. Huichen Guo

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/182762

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).